HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fang, H. Articles by Frucht, D. M. Search for Related Content PubMed PubMed Citation Articles by Fang, H. Articles by Frucht, D. M.

Anthrax Lethal Toxin Has Direct and Potent Inhibitory Effects on B Cell Proliferation and Immunoglobulin Production¹

Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD 20892

Protective host immune responses to anthrax infection in humans and animal models are characterized by the development of neutralizing Abs against the receptor-binding anthrax protective Ag (PA), which, together with the lethal factor (LF) protease, composes anthrax lethal toxin (LT). We now report that B cells, in turn, are targets for LT. Anthrax PA directly binds primary B cells, resulting in the LF-dependent cleavage of the MAPK kinases (MAPKKs) and disrupted signaling to downstream MAPK targets. Although not directly lethal to B cells, anthrax LT treatment causes severe B cell dysfunction, greatly reducing proliferative responses to IL-4-, anti-IgM-, and/or anti-CD40 stimulation. Moreover, B cells treated with anthrax LT in vitro or isolated from mice treated with anthrax LT in vivo have a markedly diminished capacity to proliferate and produce IgM in response to TLR-2 and TLR-4 ligands. The suppressive effects of anthrax LT on B cell function occur at picomolar concentrations in vitro and at sublethal doses in vivo. These results indicate that anthrax LT directly inhibits the function of B cells in vitro and in vivo, revealing a potential mechanism through which the pathogen could bypass protective immune responses.

This article has been cited by other articles:

				C. L. Loving, M. Osorio, Y.-G. Kim, G. Nunez, M. A. Hughes, and T. J. Merkel Nod1/Nod2-Mediated Recognition Plays a Critical Role in Induction of Adaptive Immunity to Anthrax after Aerosol Exposure Infect. Immun., October 1, 2009; 77(10): 4529 - 4537. [Abstract] [Full Text] [PDF]

				J. Skoble, J. W. Beaber, Y. Gao, J. A. Lovchik, L. E. Sower, W. Liu, W. Luckett, J. W. Peterson, R. Calendar, D. A. Portnoy, et al. Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax Infect. Immun., April 1, 2009; 77(4): 1649 - 1663. [Abstract] [Full Text] [PDF]

				A. M. deCathelineau and G. M. Bokoch Inactivation of Rho GTPases by Statins Attenuates Anthrax Lethal Toxin Activity Infect. Immun., January 1, 2009; 77(1): 348 - 359. [Abstract] [Full Text] [PDF]

				L. Xu, H. Fang, and D. M. Frucht Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways J. Immunol., March 15, 2008; 180(6): 4139 - 4147. [Abstract] [Full Text] [PDF]

				S.-D. Ha, D. Ng, S. L. Pelech, and S. O. Kim Critical Role of the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase-3 Signaling Pathway in Recovery from Anthrax Lethal Toxin-induced Cell Cycle Arrest and MEK Cleavage in Macrophages J. Biol. Chem., December 14, 2007; 282(50): 36230 - 36239. [Abstract] [Full Text] [PDF]

				K. Sherer, Y. Li, X. Cui, and P. Q. Eichacker Lethal and Edema Toxins in the Pathogenesis of Bacillus anthracis Septic Shock: Implications for Therapy Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 211 - 221. [Abstract] [Full Text] [PDF]